San Diego-based therapeutics company Gossamer Bio has secured $150 million in post IPO debt funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced May 2 and financed by MidCap Financial.
According to its Crunchbase profile, "Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology."
The four-year-old startup has raised two previous funding rounds, including a $230 million Series B round in 2018.
The round brings total funding raised by San Diego companies in biotechnology over the past month to $374 million, and increase of $367 million from the month before. The local biotechnology industry has seen 54 funding rounds over the past year, securing a total of $2.2 billion in venture funding.
In other local funding news, analytics company Tealium announced a $55 million Series F funding round on May 15, led by Silver Lake Waterman.
According to Crunchbase, "Founded in 2008, Tealium is the leader in enterprise tag management and digital data distribution. Tealium brings order to marketing chaos and serves as a foundational data layer for all marketing cloud applications. Hundreds of top brands worldwide rely on Tealium to seamlessly manage their digital marketing deployments."
Founded in 2008, the company has raised eight previous rounds, including a Series E round in 2017.
This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.
